文献速递胸部肿瘤支持与姑息治疗

非小细胞肺癌患者接受EGFR酪氨酸激酶抑制剂治疗期间乙型肝炎病毒再激活的发生率

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
PubMed 文献 · Eur J Cancer · 2019-07-03

该研究纳入171例HBsAg阳性的非小细胞肺癌患者,评估接受EGFR酪氨酸激酶抑制剂治疗期间HBV再激活的发生率。结论认为接受EGFR TKI治疗的患者存在有临床意义的HBV再激活风险,建议监测肝功能、HBV病毒载量及血清学。

要点

  • HBsAg阳性NSCLC患者接受EGFR TKI治疗期间HBV再激活率为9.36%,年发生率7.86%。
  • 再激活见于厄洛替尼、吉非替尼、奥希替尼和阿法替尼治疗患者。
  • 未识别出HBV再激活的独立危险因素。

核心结论

  • HBsAg阳性NSCLC患者接受EGFR TKI治疗期间存在有临床意义的HBV再激活风险。

研究设计与样本

  • 回顾性纳入2011年至2017年诊断的171例HBsAg阳性NSCLC患者,均接受EGFR TKI治疗至少2周。

主要发现

  • 中位EGFR TKI治疗时间为10.5个月(95%CI:8.2-12.8)。
  • HBV再激活发生于厄洛替尼治疗6例、吉非替尼5例、奥希替尼3例、阿法替尼2例。
  • 未发现HBV再激活的独立危险因素。

关键数值与推荐

  • HBV再激活定义为HBV DNA较基线升高至少10倍,或绝对升高至>10^5 IU/mL并伴肝功能异常。

临床怎么用

  • 对HBsAg阳性NSCLC患者,在EGFR TKI治疗期间监测肝功能、HBV病毒载量及HBV血清学(HBeAg和anti-HBc)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reactivation of hepatitis B virus (HBV) is a documented risk during cytotoxic chemotherapy in patients with lung cancer. Cases of HBV reactivation in non-small-cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment have been reported; however, the incidence of HBV reactivation in patients treated with EGFR TKIs has not yet been reported. MATERIALS AND METHODS: We enrolled 171 patients who were diagnosed as having NSCLC from 2011 through 2017 and who also had positive hepatitis B surface antigen (HBsAg). All patients had received EGFR TKIs as anticancer treatment for at least 2 weeks during their treatment course. Reactivation of HBV is defined as one of the following: an increase in HBV DNA by at least 10-fold compared to baseline or an absolute increase to >10ˆ5 IU/mL with abnormal liver function. RESULTS: The median duration of EGFR TKI treatment was 10.5 months (95% confidence interval: 8.2-12.8). Sixteen (9.36%) patients met the criteria of HBV reactivation during EGFR TKI treatment, with an annual incidence of 7.86%. HBV reactivation occurred during erlotinib treatment in 6 patients, followed by 5 patients with gefitinib treatments, 3 patients with osimertinib treatment and 2 with afatinib treatment. No independent risk factor for HBV reactivation was identified. CONCLUSION: NSCLC patients receiving EGFR TKI treatment may have a clinically meaningful risk of HBV reactivation during the treatment period. Thus, monitoring liver function, HBV viral load and serology of HBV (i.e., HBeAg and anti-HBc) during EGFR TKI therapy is recommended for NSCLC patients with positive HBsAg.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yao ZH, Liao WY, Ho CC, et al. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer. 2019. PMID: 31279301. doi:10.1016/j.ejca.2019.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。